About: Dexmedetomidine in Enhanced Recovery After Surgery (ERAS) Protocols for Postoperative Pain

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dexmedetomidine in Enhanced Recovery After Surgery (ERAS) Protocols for Postoperative Pain Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Dexmedetomidine in Enhanced Recovery After Surgery (ERAS) Protocols for Postoperative Pain
Creator	Chernobylsky, David Cornett, Elyse Eng, Lauren Harbell, Monica Kaye, Alan Kaye, Rachel Lajaunie, Jared Siddaiah, Harish Thakur, Pankaj
source	PMC
abstract	PURPOSE OF REVIEW: Effective acute pain management has evolved considerably in recent years and is a primary area of focus in attempts to defend against the opioid epidemic. Persistent postsurgical pain (PPP) has an incidence of up to 30–50% and has negative outcome of quality of life and negative burden on individuals, family, and society. The 2016 American Society of Anesthesiologists (ASA) guidelines states that enhanced recovery after surgery (ERAS) forms an integral part of Perioperative Surgical Home (PSH) and is now recommended to use a multimodal opioid-sparing approach for management of postoperative pain. As such, dexmedetomidine is now being used as part of ERAS protocols along with regional nerve blocks and other medications, to create a satisfactory postoperative outcome with reduced opioid consumption in the Post anesthesia care unit (PACU). RECENT FINDINGS: Dexmedetomidine, a selective alpha(2) agonist, possesses analgesic effects and has a different mechanism of action when compared with opioids. When dexmedetomidine is initiated at the end of a procedure, it has a better hemodynamic stability and pain response than ropivacaine. Dexmedetomidine can be used as an adjuvant in epidurals with local anesthetic sparing effects. Its use during nerve blocks results in reduced postoperative pain. Also, local infiltration of IV dexmedetomidine is associated with earlier discharge from PACU. SUMMARY: Perioperative use of dexmedetomidine has significantly improved postoperative outcomes when used as part of ERAS protocols. An in-depth review of the use of dexmedetomidine in ERAS protocols is presented for clinical anesthesiologists.
has issue date	2020-04-02(xsd:dateTime)
bibo:doi	10.1007/s11916-020-00853-z
bibo:pmid	32240402
has license	no-cc
sha1sum (hex)	7bce539e82301a76fc6c8cdbf0d6e1da348e3589
schema:url	https://doi.org/10.1007/s11916-020-00853-z
resource representing a document's title	Dexmedetomidine in Enhanced Recovery After Surgery (ERAS) Protocols for Postoperative Pain
has PubMed Central identifier	PMC7223065
has PubMed identifier	32240402
schema:publication	Curr Pain Headache Rep
resource representing a document's body	covid:7bce539e82301a76fc6c8cdbf0d6e1da348e3589#body_text
is schema:about of	named entity 'Recovery' named entity 'non-steroidal anti-inflammatory drugs' named entity 'analgesic' named entity 'comorbidity' named entity 'muscle weakness' named entity 'nerve blocks' named entity 'dexmedetomidine' named entity 'loading dose' named entity 'Dexmedetomidine' named entity 'bradycardia' named entity 'prophylactically' named entity 'postoperative pain' named entity 'sympathetic outflow' named entity 'volume of distribution' named entity 'paresthesia' named entity 'ICU' named entity 'PACU' named entity 'meta-analysis' named entity 'dry mouth' named entity 'bradycardia' named entity 'buccal' named entity 'double-blinded' named entity 'peripheral nerve' named entity 'pediatric patients' named entity 'opioid' named entity 'dexmedetomidine' named entity 'intrathecal' named entity 'opioids' named entity 'Intramuscular' named entity 'brachial plexus' named entity 'c-section' named entity 'animal models' named entity 'blood flow' named entity 'presynaptic' named entity 'PACU' named entity 'opioid' named entity 'Dexmedetomidine' named entity 'respiratory drive' named entity 'dexmedetomidine' named entity 'sedation' named entity 'agonist' named entity 'dexmedetomidine' named entity 'statistically significant' named entity 'nerve blocks' named entity 'opioid' named entity 'buccal administration' named entity 'infusion' named entity 'adenosine monophosphate' named entity 'Analgesia' named entity 'breast milk' named entity 'protein-bound' named entity 'sedation' named entity 'volume of distribution' named entity 'sedation' named entity 'neonatal' named entity 'lipophilic' named entity 'dexmedetomidine' named entity 'sedation' named entity 'transmucosal' named entity 'dexmedetomidine' named entity 'catecholamines' named entity 'pregnancy' named entity 'opioid' named entity 'nerve conduction' named entity 'sevoflurane' named entity 'dexmedetomidine' named entity 'alpha-2 receptor' named entity 'emergence delirium' named entity 'Dexmedetomidine' named entity 'ICU' named entity 'atipamezole' named entity 'supportive therapy' named entity 'dexmedetomidine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software